Yi-Qi-Pin-Chuan granules: a Chinese medicine for treatment of acute asthma

Not Applicable

Completed

• Conditions: Mild to moderate asthma in acute exacerbation; Respiratory; Asthma

• Registration Number: ISRCTN61674768
• Lead Sponsor: West China Hospital at Sichuan University (China)

Brief Summary

2018 results in: https://www.ncbi.nlm.nih.gov/pubmed/29957279

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-07-29
• Study Completion: 2010-12-31
• Last Update Posted: 30 July 2018

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

1. Mild to moderate asthma in acute exacerbation
2. Male and female patients between 15 and 75 years
3. Within 72 hours of onset of acute asthma
4. Ability to provide written informed consent

Exclusion Criteria

1. Use of systemic steroids or immunosuppressive agents within one month before recruitment, or history of life-threatening asthma requiring treatment with intubation and mechanical ventilation
2. Maintenance therapy with symbicort, or rescue therapy with formoterol or anticholinergic agents
3. Allergies to any components Yi-Qi-Pin-Chuan granule, as Chinese medicine
4. Current alcoholism or drug abuse
5. Lung diseases other asthma
6. Severe diseases of cardiovascular, hepatic, renal, central nervous system, haematopoietic system cancer
7. Significant medical illness (other than asthma) that is not stable
8. History of respiratory tract infection within the previous 6 weeks
9. Pregnancy or breastfeeding
10. The inability to understand and complete this study
11. Peptic ulcer or gastrointestinal haemorrhage
12. Intolerance to beta-2-agonists or steroids

Study & Design

• Study Type: Interventional
• Study Design: Not specified